CIK: 0001974915
Total reported value
$3.6B
Reporting period: 2026-03-31 · Number of holdings: 90
Vestal Point Capital, LP disclosed 90 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $3.6B and a quarterly turnover rate of 103.4%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "V"
Vestal Point Capital, LP's disclosed holdings carry a Herfindahl concentration index of 0.026 — mathematically equivalent to about 39 equally-sized positions, well below its 90 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 1.15), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 40% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add RVMD
+705.1% $207.5M
Trim 430
-77.8% -$129.1M
Trim ABVX
-21.1% -$89.2M
Add RGEN
+1014.5% $95.4M
Trim GMED
-52.1% -$58.7M
Trim TYRA
-97.8% -$61.7M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines INC | Stock-Healthcare | 6.46% | +5.66% | +705.08% | |
| 2 | BMRN | Biomarin Pharmaceutical INC | Stock-Healthcare | 5.65% | -0.41% | +19.17% | |
| 3 | ABVX | Abivax Sa-adr | Stock-Other | 4.67% | -4.04% | -21.05% | |
| 4 | NBIX | Neurocrine Biosciences INC | Stock-Healthcare | 4.60% | +4.60% | NEW | |
| 5 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 3.99% | +1.96% | +152.78% | |
| 6 | ELVN | Enliven Therapeutics INC | Stock-Other | 3.56% | +1.55% | -15.14% | |
| 7 | RGEN | Repligen CORP | Stock-Healthcare | 3.05% | +2.59% | +1014.46% | |
| 8 | BCAX | Bicara Therapeutics INC | Stock-Other | 3.02% | +0.97% | +51.75% | |
| 9 | NRIX | Nurix Therapeutics INC | Stock-Other | 2.82% | — | +38.59% | |
| 10 | APGE | Apogee Therapeutics INC | Stock-Other | 2.59% | +1.18% | +100.00% | |
| 11 | ASND | Ascendis Pharma A/S | Stock-Other | 2.40% | +1.13% | +114.29% | |
| 12 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 2.33% | +1.64% | +372.97% | |
| 13 | TSHA | Taysha Gene Therapies INC | Stock-Other | 2.25% | — | +30.91% | |
| 14 | DYN | Dyne Therapeutics INC | Stock-Other | 2.03% | +1.95% | +3233.33% | |
| 15 | SNY | Sanofi-adr | Stock-Healthcare | 1.89% | +1.89% | NEW | |
| 16 | BCRX | Biocryst Pharmaceuticals INC | Stock-Other | 1.87% | +1.27% | +212.22% | |
| 17 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.82% | +0.77% | +89.20% | |
| 18 | ✓ | Immatics NV | Stock-Other | 1.70% | — | +0.82% | |
| 19 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 1.70% | +1.24% | +300.00% | |
| 20 | ALC | Alcon Inc. | Stock-Healthcare | 1.69% | -1.27% | -27.60% | |
| 21 | GLUE | Monte Rosa Therapeutics INC | Stock-Other | 1.66% | +1.25% | +364.96% | |
| 22 | VERA | Vera Therapeutics INC | Stock-Other | 1.54% | +0.59% | +148.76% | |
| 23 | 430 | Terns Pharmaceuticals INC | Stock-Other | 1.47% | -4.71% | -77.78% | |
| 24 | GMED | Globus Medical INC - A | Stock-Healthcare | 1.47% | -2.31% | -52.12% | |
| 25 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.40% | +1.40% | NEW | |
| 26 | NUVL | Nuvalent Inc-a | Stock-Other | 1.38% | +1.22% | +947.21% | |
| 27 | COGT | Cogent Biosciences INC | Stock-Other | 1.32% | +1.32% | NEW | |
| 28 | ANRO | Alto Neuroscience INC | Stock-Other | 1.30% | — | -16.94% | |
| 29 | RAPP | Rapport Therapeutics INC | Stock-Other | 1.26% | — | +29.39% | |
| 30 | IRON | Disc Medicine INC | Stock-Other | 1.25% | — | -4.76% | |
| 31 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.24% | +1.24% | NEW | |
| 32 | CLDX | Celldex Therapeutics INC | Stock-Other | 1.09% | — | +5.08% | |
| 33 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 1.04% | — | -2.12% | |
| 34 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 1.04% | — | +6.65% | |
| 35 | SLDB | Solid Biosciences INC | Stock-Other | 1.01% | — | -14.02% | |
| 36 | DRUG | Bright Minds Biosciences INC | Stock-Other | 1.00% | +1.00% | NEW | |
| 37 | PTGX | Protagonist Therapeutics INC | Stock-Other | 0.96% | +0.96% | NEW | |
| 38 | DNLI | Denali Therapeutics INC | Stock-Other | 0.95% | +0.69% | +281.36% | |
| 39 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.86% | +0.86% | NEW | |
| 40 | WAT | Waters CORP | Stock-Healthcare | 0.83% | +0.83% | NEW | |
| 41 | VKTX | Viking Therapeutics INC | Stock-Healthcare | 0.83% | +0.83% | NEW | |
| 42 | INSP | Inspire Medical Systems INC | Stock-Healthcare | 0.78% | +0.78% | NEW | |
| 43 | ✓ | Crescent Biopharma INC. | Stock-Other | 0.77% | — | — | |
| 44 | TRVI | Trevi Therapeutics INC | Stock-Other | 0.72% | +0.72% | NEW | |
| 45 | LXEO | Lexeo Therapeutics INC | Stock-Other | 0.72% | — | — | |
| 46 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 0.68% | +0.68% | NEW | |
| 47 | BBNX | Beta Bionics INC | Stock-Other | 0.62% | — | +268.59% | |
| 48 | NKTR | Nektar Therapeutics | Stock-Other | 0.57% | +0.57% | NEW | |
| 49 | CYTK | Cytokinetics INC | Stock-Healthcare | 0.55% | +0.55% | NEW | |
| 50 | AZN | AstraZeneca PLC | Stock-Healthcare | 0.55% | +0.55% | NEW |
Performance for Q3 2026
+19.1%
Performance Last 4 Quarters
+116%
Based on 72% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 90 | $3.6B | 100 | |
| 2025-12-31 | 76 | $2.9B | 100 | |
| 2025-09-30 | 81 | $2.2B | 96 | |
| 2025-06-30 | 72 | $1.9B | 0 | |
| 2025-03-31 | 63 | $1.4B | 0 | |
| 2024-12-31 | 73 | $1.7B | 0 | |
| 2024-09-30 | 69 | $1.3B | 0 | |
| 2024-06-30 | 60 | $1.3B | 0 | |
| 2024-03-31 | 58 | $1.2B | 0 | |
| 2023-12-31 | 48 | $944.0M | 0 |
Vestal Point Capital, LP's most significant position changes for 2026-03-31: Sold out: Invesco Qqq Trust Series 1 (QQQ); Sold out: Arcellx INC (ACLXGBX); New buy: Neurocrine Biosciences INC (NBIX); Sold out: Dexcom INC (DXCM); Sold out: Merck & Co. INC. (MRK).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines INC | +5.7% | +705.08% | Add |
| 2 | RGEN | Repligen CORP | +2.6% | +1014.46% | Add |
| 3 | ARWR | Arrowhead Pharmaceuticals In | +2% | +152.78% | Add |
| 4 | DYN | Dyne Therapeutics INC | +2% | +3233.33% | Add |
| 5 | IMCR | Immunocore Holdings Plc-adr | +1.6% | +372.97% | Add |
| 6 | ELVN | Enliven Therapeutics INC | +1.6% | -15.14% | Trim |
| 7 | BCRX | Biocryst Pharmaceuticals INC | +1.3% | +212.22% | Add |
| 8 | GLUE | Monte Rosa Therapeutics INC | +1.3% | +364.96% | Add |
| 9 | BMY | Bristol-myers Squibb Co | +1.2% | +300.00% | Add |
| 10 | NUVL | Nuvalent Inc-a | +1.2% | +947.21% | Add |
| 11 | APGE | Apogee Therapeutics INC | +1.2% | +100.00% | Add |
| 12 | ASND | Ascendis Pharma A/S | +1.1% | +114.29% | Add |
| 13 | BCAX | Bicara Therapeutics INC | +1% | +51.75% | Add |
| 14 | SRRK | Scholar Rock Holding CORP | +0.8% | +89.20% | Add |
| 15 | DNLI | Denali Therapeutics INC | +0.7% | +281.36% | Add |
| 16 | VERA | Vera Therapeutics INC | +0.6% | +148.76% | Add |
| 17 | BMRN | Biomarin Pharmaceutical INC | -0.4% | +19.17% | Add |
| 18 | OLMA | Olema Pharmaceuticals INC | -1.2% | -74.03% | Trim |
| 19 | ALC | Alcon Inc. | -1.3% | -27.60% | Trim |
| 20 | TYRA | Tyra Biosciences INC | -2.1% | -97.77% | Trim |
| 21 | GMED | Globus Medical INC - A | -2.3% | -52.12% | Trim |
| 22 | ABVX | Abivax Sa-adr | -4% | -21.05% | Trim |
| 23 | 430 | Terns Pharmaceuticals INC | -4.7% | -77.78% | Trim |
| 24 | QQQ | Invesco Qqq Trust Series 1 | — | EXIT | Sold out |
| 25 | ACLXGBX | Arcellx INC | — | EXIT | Sold out |
| 26 | NBIX | Neurocrine Biosciences INC | — | NEW | New buy |
| 27 | DXCM | Dexcom INC | — | EXIT | Sold out |
| 28 | MRK | Merck & Co. INC. | — | EXIT | Sold out |
| 29 | ABT | Abbott Laboratories | — | EXIT | Sold out |
| 30 | SNY | Sanofi-adr | — | NEW | New buy |
| 31 | BSX | Boston Scientific CORP | — | NEW | New buy |
| 32 | JAZZ | Jazz Pharmaceuticals plc | — | EXIT | Sold out |
| 33 | DAWNGBX | Day One Biopharmaceuticals I | — | EXIT | Sold out |
| 34 | COGT | Cogent Biosciences INC | — | NEW | New buy |
| 35 | UTHR | United Therapeutics CORP | — | NEW | New buy |
| 36 | AXSM | Axsome Therapeutics INC | — | EXIT | Sold out |
| 37 | DRUG | Bright Minds Biosciences INC | — | NEW | New buy |
| 38 | PTGX | Protagonist Therapeutics INC | — | NEW | New buy |
| 39 | REGN | Regeneron Pharmaceuticals | — | NEW | New buy |
| 40 | WAT | Waters CORP | — | NEW | New buy |
| 41 | VKTX | Viking Therapeutics INC | — | NEW | New buy |
| 42 | INSP | Inspire Medical Systems INC | — | NEW | New buy |
| 43 | TRVI | Trevi Therapeutics INC | — | NEW | New buy |
| 44 | SLNOEUR | Soleno Therapeutics INC | — | NEW | New buy |
| 45 | LNTH | Lantheus Holdings INC | — | EXIT | Sold out |
| 46 | ZYME | Zymeworks INC | — | EXIT | Sold out |
| 47 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 48 | CYTK | Cytokinetics INC | — | NEW | New buy |
| 49 | AZN | AstraZeneca PLC | — | NEW | New buy |
| 50 | UPB | Upstream Bio INC | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-14 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001730242
Total reported value
$3.6B
580 stks
2022-09-30
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001855713
Total reported value
$3.6B
519 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001715696
Total reported value
$3.6B
1 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001687444
Total reported value
$124.7M
18 stks
2026-03-31
2 of the top 5 holdings overlap, including Abivax Sa-adr
CIK 0001727492
Total reported value
$1.5B
28 stks
2026-03-31
2 of the top 5 holdings overlap, including Revolution Medicines INC
CIK 0001839209
Total reported value
$3.8B
6 stks
2026-03-31
2 of the top 5 holdings overlap, including Abivax Sa-adr